2011 (11 POSTS)
Kim S, Thompson CM , Kopec AK, Harris MA, Zacharewski TR. Comparison of basal and CrVI-mediated solute carrier gene expression in rodent duodenal epithelium. Presented at Society of Toxicology 50th Annual Meeting, Washington, DC, March 2011.
View Abstract
Topics: chromium
Proctor D, Haws L , Thompson C , Harris M. 2011. Use of mode of action and pharmacokinetics to inform the cancer risk assessment of ingested Cr(VI): A case study. Presented at the Society of Toxicology 50th Annual Meeting, Washington, DC, March 2011.
View Abstract
Topics: Cancer , chromium , mode of action , pharmacokinetics , risk assessment
2010 (2 POSTS)
Johns DO, Owens EO, Thompson CM , Sonawane B, Hattis D, Krishnan K. 2010. Physiological parameters and databases for PBPK modeling. Chapter 5 in: Quantitative Modeling in Toxicology. Krishnan K, Andersen M (eds.). Wiley, p. 107.
View Abstract
Topics: modeling , PBPK/PBDE
Thompson CM , Ceder R, Grafström RC. 2010. Formaldehyde dehydrogenase: Beyond phase I metabolism. Toxicol Lett 193(1):1-3; doi: 10.1016/j.toxlet.2009.11.023 .
View Abstract
Topics: formaldehyde
2009 (3 POSTS)
Thompson CM , Grafstrom RC. 2009. Commentary: Mechanistic considerations for associations between formaldehyde exposure and nasopharyngeal carcinoma. Environ Health 8:53; doi: 10.1186/1476-069X-8-53 .
View Abstract
Topics: Cancer , formaldehyde , Occupational
Thompson CM , Sonawane B, Grafström RC. 2009. The ontogeny, distribution and regulation of alcohol dehydrogenase 3: Implications for pulmonary physiology. Drug Metab Disposit 37(8):1565-1571; doi: 10.1124/dmd.109.027904 .
View Abstract
Topics: Exposure Assessment , formaldehyde
Thompson CM , Johns DO, Sonawane S, Barton HA, Hattis D, Tardif R, Krishnan K. 2009. Database for physiologically based pharmacokinetic (PBPK) modeling: Physiological parameters for healthy and health-impaired elderly. J Toxicol Environ Health B 12(1):1–24; doi: 10.1080/10937400802545060 .
View Abstract
Topics: modeling , PBPK/PBDE , pharmacokinetics
2008 (5 POSTS)
DeWoskin RS, Thompson CM. 2008. Renal clearance parameters for PBPK model analysis of early lifestage differences in the disposition of environmental toxicants. Regul Toxicol Pharmacol 51(June):66–86; doi: 10.1016/j.yrtph.2008.02.005 .
View Abstract
Topics: modeling , PBPK/PBDE
Makris SL, Thompson CM , Euling SY, Selevan SG, Sonawane B. 2008. A lifestage-specific spproach to hazard and dose-response characterization for children’s health risk assessment. Birth Defects Res B 83(6):530–546; doi: 10.1002/bdrb.20176 .
View Abstract
Topics: risk assessment
Subramaniam RP, Chen C, Crump KS, Devoney D, Fox JF, Portier CJ, Schlosser PM, Thompson CM , White P. 2008. Uncertainties in biologically-based modeling of formaldehyde-induced respiratory cancer risk: Identification of key issues. Risk Analysis 28(4):907–923; doi: 10.1111/j.1539-6924.2008.01083.x .
View Abstract
Topics: Cancer , Exposure Assessment , formaldehyde , risk assessment
Thompson CM , Subramaniam RP, Grafström RC. 2008. Mechanistic and dose considerations for supporting adverse pulmonary physiology in response to formaldehyde. Toxicol Appl Pharmacol 233(3):355–359.
View Abstract
Topics: formaldehyde
Thompson CM , Sonawane B, Barton HA, DeWoskin RS, Schlosser P, Lipscomb JC, Chiu W, Krishnan K. 2008. Approaches for applications of physiologically based pharmacokinetic models in risk assessment. J Toxicol Environ Health B 11(7):519–547; doi: 10.1080/10937400701724337 .
View Abstract
Topics: modeling , PBPK/PBDE , pharmacokinetics , risk assessment
2007 (1 POST)
Thompson CM , Grafström RC. 2007. Mechanistic considerations for formaldehyde-induced bronchoconstriction involving S-nitrosoglutathione reductase. J Toxicol Environ Health A 71:244–248; doi: 10.1080/15287390701598259 .
View Abstract
Topics: formaldehyde
2006 (1 POST)
Barone S Jr., Brown RC, Euling S, Cohen Hubal E, Kimmel CA, Makris S, Moya J, Selevan SG, Sonawane B, Thomas T, Thompson CM . 2006. Visión general de la evaluación del rieso en salud infantil empleando un enfoque por etapas de desarrollo. Acta Toxicol Argent 14(Suppl):7–10.
Topics: Epidemiology
2004 (1 POST)
Thompson CM , Wojno H, Greiner E, May EL, Rice KC, Selley DE. 2004. Activation of G-proteins by morphine and codeine congeners: Insights to the relevance of O- and N-demethylated metabolites at μ- and δ-opioid receptors. J Pharmacol Exper Therapeut 308(2):547–554; PMID: 14600248 .
View Abstract
Topics: Toxicology
2002 (1 POST)
Strobel HW, Thompson CM , Antonovic L. 2001. Cytochromes P450 in brain: Function and significance. Curr Drug Metabol 2(2):199–214; doi: 10.2174/1389200013338577 .
View Abstract
Topics: Toxicology
2000 (1 POST)
Thompson CM , Capdevila JH, Strobel HW. 2000. Recombinant P450 2D18 metabolism of dopamine and arachidonic acid. J Pharmacol Exper Ther 294(3):1120–1130; doi: 10.1016/S0022-3565(24)39180-3 .
View Abstract
Topics: pharmacokinetics
1998 (2 POSTS)
Gerhardt B, Kordas TJ, Thompson CM , Patel P, Vida TV. 1998. The vesicle transport protein, Vps33p, is an ATP binding protein that localizes to the cytosol in an energy dependent manner. J Biol Chem 273(25):15818–15829; doi: 10.1074/jbc.273.25.15818 .
View Abstract
Topics: Toxicology
Thompson CM , Kawashima H, and Strobel HW. 1998. Isolation of partially purified P450 2D18 and characterization of activity towards the tricyclic antidepressants imipramine and desipramine. Arch Biochem Biophys 359(1):115–121; doi: 10.1006/abbi.1998.0892 .
View Abstract
Topics: drug interactions
1997 (2 POSTS)
Kawashima H, Kusunose E, Thompson CM , and Strobel HW. 1997. Protein expression, characterization, and regulation of CYP4F4 and CYP4F5 cloned from rat brain. Arch Biochem Biophys 347(1):148–154 doi: 10.1006/abbi.1997.0342 .
View Abstract